Icon snaps up molecular Dx specialist MolecularMD for undisclosed price

Laboratory
The purchase expands Icon’s laboratory offering in molecular diagnostic testing. (Getty/RossHelen)

Icon, a CRO based in Dublin, has acquired MolecularMD, a molecular diagnostic specialty lab that focuses on a platform for the development and commercialization of precision medicines for oncology.

Financial terms of the deal weren’t disclosed.

The purchase expands Icon’s laboratory offering in molecular diagnostic testing and brings expanded testing platforms, including next generation sequencing and immunohistochemistry (IHC), the company said.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

MolecularMD, which was founded in 2006, offers a comprehensive test menu in the area of immune oncology development at its labs in Portland, Oregon, and Cambridge, Massachusetts. The company also offers companion diagnostic development services.

“We are committed to expanding the testing we offer into specialized areas so that we can help customers to take time and cost from the development and commercialization of precision medicines,” Steve Cutler, Icon’s CEO, said in a statement.

RELATED: Irish CRO Icon rolls out digital platform developed with Dimension Data

Last month, Icon adopted a new digital platform developed with Dimension Data that was designed to enhance efficiency and productivity of its client’s drug and medical device pipelines. The platform was rolled out throughout the CRO to help support digital trials and patient interactions.

Suggested Articles

There are thousands of clinical trials ongoing around the world, but only a small percentage of patients participate. Icon is hoping to change that.

Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.

To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.